Bausch Health Companies Inc. (BHC)
Pre-market:
| Previous close | 8.53 |
| Open | 8.54 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 2200 |
| Day's range | 8.45 - 8.59 |
| 52-week range | 5.57 - 11.46 |
| Volume | |
| Avg. volume | 2,820,504 |
| Market cap | 3.148B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 Nov 2010 |
| 1y target est | 10.17 |
ZacksAnalysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insider Monkey10 Best Healthcare Stocks to Buy Under $20
In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]
- Reuters
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals.
